201 related articles for article (PubMed ID: 29785514)
1. Correlation of dose with toxicity and tumour response to
Cremonesi M; Ferrari ME; Bodei L; Chiesa C; Sarnelli A; Garibaldi C; Pacilio M; Strigari L; Summers PE; Orecchia R; Grana CM; Botta F
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2426-2441. PubMed ID: 29785514
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of simplifying renal dosimetry in
Sundlöv A; Gustafsson J; Brolin G; Mortensen N; Hermann R; Bernhardt P; Svensson J; Ljungberg M; Tennvall J; Sjögreen Gleisner K
EJNMMI Phys; 2018 Jul; 5(1):12. PubMed ID: 29974391
[TBL] [Abstract][Full Text] [Related]
3. Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy.
O'Neill E; Cornelissen B
Nucl Med Biol; 2022; 108-109():44-53. PubMed ID: 35276447
[TBL] [Abstract][Full Text] [Related]
4. Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review.
Gape PMD; Schultz MK; Stasiuk GJ; Terry SYA
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543120
[TBL] [Abstract][Full Text] [Related]
5. Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy.
Persson M; Hindorf C; Ardenfors O; Larsson M; Nilsson JN
EJNMMI Res; 2024 Feb; 14(1):13. PubMed ID: 38319478
[TBL] [Abstract][Full Text] [Related]
6. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations.
Gear JI; Cox MG; Gustafsson J; Gleisner KS; Murray I; Glatting G; Konijnenberg M; Flux GD
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2456-2474. PubMed ID: 30218316
[TBL] [Abstract][Full Text] [Related]
7. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.
Strigari L; Konijnenberg M; Chiesa C; Bardies M; Du Y; Gleisner KS; Lassmann M; Flux G
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1976-88. PubMed ID: 24915892
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force.
Stokke C; Gabiña PM; Solný P; Cicone F; Sandström M; Gleisner KS; Chiesa C; Spezi E; Paphiti M; Konijnenberg M; Aldridge M; Tipping J; Wissmeyer M; Brans B; Bacher K; Kobe C; Flux G
EJNMMI Phys; 2017 Nov; 4(1):27. PubMed ID: 29164483
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers and Imaging for Precision Radiotherapy.
West CM; Huddart RA
Clin Oncol (R Coll Radiol); 2015 Oct; 27(10):545-6. PubMed ID: 26173954
[No Abstract] [Full Text] [Related]
10. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized
Del Prete M; Arsenault F; Saighi N; Zhao W; Buteau FA; Celler A; Beauregard JM
EJNMMI Phys; 2018 Oct; 5(1):25. PubMed ID: 30318563
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review.
Huizing DMV; de Wit-van der Veen BJ; Verheij M; Stokkel MPM
EJNMMI Res; 2018 Aug; 8(1):89. PubMed ID: 30159614
[TBL] [Abstract][Full Text] [Related]
12. Personalized radiation dosimetry for PRRT-how many scans are really required?
Freedman N; Sandström M; Kuten J; Shtraus N; Ospovat I; Schlocker A; Even-Sapir E
EJNMMI Phys; 2020 May; 7(1):26. PubMed ID: 32394075
[TBL] [Abstract][Full Text] [Related]
13. PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
Haug AR
EJNMMI Res; 2020 Apr; 10(1):35. PubMed ID: 32296955
[TBL] [Abstract][Full Text] [Related]
14. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
15. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors.
Jahn U; Ilan E; Sandström M; Garske-Román U; Lubberink M; Sundin A
Neuroendocrinology; 2020; 110(7-8):662-670. PubMed ID: 31597134
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Voxel-Based Dosimetry in Theranostics: a Review.
Gupta A; Lee MS; Kim JH; Lee DS; Lee JS
Nucl Med Mol Imaging; 2020 Apr; 54(2):86-97. PubMed ID: 32377260
[TBL] [Abstract][Full Text] [Related]
17. MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee.
Bolch WE; Bouchet LG; Robertson JS; Wessels BW; Siegel JA; Howell RW; Erdi AK; Aydogan B; Costes S; Watson EE; Brill AB; Charkes ND; Fisher DR; Hays MT; Thomas SR
J Nucl Med; 1999 Jan; 40(1):11S-36S. PubMed ID: 9935083
[TBL] [Abstract][Full Text] [Related]
18. Comparison of commercial dosimetric software platforms in patients treated with
Mora-Ramirez E; Santoro L; Cassol E; Ocampo-Ramos JC; Clayton N; Kayal G; Chouaf S; Trauchessec D; Pouget JP; Kotzki PO; Deshayes E; Bardiès M
Med Phys; 2020 Sep; 47(9):4602-4615. PubMed ID: 32632928
[TBL] [Abstract][Full Text] [Related]
19. Kidney dosimetry in 777 patients during
Sandström M; Freedman N; Fröss-Baron K; Kahn T; Sundin A
EJNMMI Phys; 2020 Dec; 7(1):73. PubMed ID: 33296054
[TBL] [Abstract][Full Text] [Related]
20. MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218).
Gugliandolo SG; Pepa M; Isaksson LJ; Marvaso G; Raimondi S; Botta F; Gandini S; Ciardo D; Volpe S; Riva G; Rojas DP; Zerini D; Pricolo P; Alessi S; Petralia G; Summers PE; Mistretta FA; Luzzago S; Cattani F; De Cobelli O; Cassano E; Cremonesi M; Bellomi M; Orecchia R; Jereczek-Fossa BA
Eur Radiol; 2021 Feb; 31(2):716-728. PubMed ID: 32852590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
